Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing
TL;DR
Keros Therapeutics filed a routine 8-K on Nov 26, 2024, for disclosures and exhibits.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on November 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a standard disclosure for Keros Therapeutics, Inc., indicating regulatory compliance and the submission of financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no new material events or financial information that would indicate increased risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- November 26, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Keros Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The 8-K filing was reported as of November 26, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive office address is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-26 08:02:51
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20241126.htm (8-K) — 38KB
- exhibit991112624pr.htm (EX-99.1) — 9KB
- 0001664710-24-000094.txt ( ) — 173KB
- kros-20241126.xsd (EX-101.SCH) — 2KB
- kros-20241126_lab.xml (EX-101.LAB) — 22KB
- kros-20241126_pre.xml (EX-101.PRE) — 13KB
- kros-20241126_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 26, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that Jasbir Seehra, the Company's Chair and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36 th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10:30 a.m. Eastern time, and a fireside chat presentation at the 7 th Annual Evercore HealthConx Conference on Wednesday, December 4, 2024 at 3:00 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 2 6, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: November 26, 2024